30results about How to "Novel sequence" patented technology

A DNA, which encodes the following polypeptide (a), (b), (c) or (d):(a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2 or 4,(b) a polypeptide consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 4 by deletion, substitution or addition of one or several amino acids, and having hypophosphatemia-inducing activity, phosphate transport-suppressing activity, calcification-suppressing activity or in vivo vitamin D metabolism-regulating activity,(c) a polypeptide consisting of a partial sequence of the amino acid sequence represented by SEQ ID NO: 2, wherein the above partial sequence contains an amino acid sequence at least ranging from the 34th to 201st amino acids in the above amino acid sequence, or(d) a polypeptide consisting of a partial sequence of the amino acid sequence represented by SEQ ID NO: 2, wherein the above partial sequence:(i) contains an amino acid sequence ranging from at least the 34th to 201st amino acids in said amino acid sequence,(ii) consists of an amino acid sequence derived from the partial sequence by deletion, substitution, or addition of one or several amino acids, and(iii) has hypophosphatemia-inducing activity, phosphate transport-suppressing activity, calcification-suppressing activity or in vivo vitamin D metabolism-regulating activity.

The invention relates to the technical field of biotechnology and biochemical detection, and in particular relates to alginate lyase and an application thereof in quantitative detection of alginate. The alginate lyase Aly7A has a novel amino acid sequence and good enzymatic properties, and the amino acid sequence of the alginate lyase Aly7A is SEQ ID NO. 1. On the basis of Aly7A, the invention discloses a quantitative detection method of alginate. The method comprises the steps that alginate lyase Aly7A and a sample to be detected are subjected to mixed reaction; alginate possibly contained inthe sample is subjected to enzymolysis; the increment of the light absorption value of a reaction system at 235 nm is detected and substituted into a standard curve; and the content of alginate in the sample to be detected can be detected. The detection method has the advantages of being high in specificity, rapid, easy and convenient to implement and the like.

The invention belongs to the technical field of biology, particularly relates to an anti-TROP2 nano antibody composed of a variable region of a heavy-chain antibody and a preparation method and application of the anti-TROP2 nano antibody, and also provides a coding nucleic acid molecule, an expression vector, a host cell and the like of the antibody. The anti-TROP2 nano-antibody (TROP2-VHH-01-9F nano-antibody and TROP2-VHH-01-5A nano-antibody) prepared by the invention has high affinity binding to a human TROP2 antigen, also has strong antibody endocytosis activity and a novel sequence, and isa new anti-TROP2 nano-antibody.

The invention relates to an anti-human PD1 monoclonal antibody and application thereof, also provides coding nucleic acid molecules of the antibody, expression carriers, host cells and a method for expressing the antibody, and also provides an antibody immune coupling binder of the antibody, bispecific molecules, chimeric antigen receptors, a pharmaceutical composition and application. Compared with the prior art, the anti-human PD1 monoclonal antibody disclosed by the invention has the following advantages that the monoclonal antibody of human PD1 can be specially identified, and the bindingaffinity of the antibody and the human PD1 is stronger than that of an existing anti-human PD1 monoclonal antibody, and a sequence of the antibody is novel.

The invention provides a marine-derived bacillus antimicrobial protein MD and a preparation method thereof and relates to a marine-derived bacillus antimicrobial protein. Supernatant is taken after bacillus culture, ammonium sulfate is added to reach the saturation of 60%, centrifugation is performed, a precipitate is taken and is dissolved in water again, dialysis, lyophilization and re-dissolution are performed to obtain a crude protein solution, then separation and purification are performed on an ethyl amino ethyl anion exchange chromatographic column, components are collected, and a staphylococcus aureus is used as a tested indicator bacterium to track active components after centrifugal ultra-filtration and concentration; the concentrated active components are separated and purified on a quaternary ammonium salt strong anion exchange column, elution components are collected, ultra-filtration and concentration are performed, the bacteriostatic activity is checked, and the component purity is judged through SDS-PAGE electrophoresis after the active components are determined; single strips on an SDS-PAGE electrophoretogram are cut to perform liquid chromatography-mass spectrometry combined detection and identification, and a whole genome encoding protein sequence is used as a database to perform comparison so as to obtain the antimicrobial protein sequence MD.

The invention belongs to the technical field of biology, relates to an anti-human SIRP alpha monoclonal antibody and application thereof, and also provides coding nucleic acid molecules, an expressionvector and a host cell of the antibody, and a method for expressing the antibody. The invention also provides an antibody immunoconjugate containing the antibody, bispecific molecules, a chimeric antigen receptor, a pharmaceutical composition, and a diagnosis and treatment method. According to the monoclonal antibody capable of specifically recognizing human SIRP alpha, the affinity of combiningthe antibody with the human SIRP alpha is higher than that of existing anti-human SIRP alpha monoclonal antibodies, and the sequence is novel.

The invention belongs to the technical field of biology, relates to an anti-human PDL1 monoclonal antibody and use thereof, and also provides a coding nucleic acid molecule, an expression vector and a host cell of the antibody, and a method for expressing the antibody. The anti-human PDL1 monoclonal antibody can specifically recognize a human PDL1 monoclonal antibody. The antibody has a higher binding affinity with human PDL1 than that of an existing anti-human PDL1 monoclonal antibody, and has a novel sequence.